Clinical Trial Update: Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating UCPVax in combination with nivolumab as second-line therapy for advanced non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• UCPVax
• nivolumab (nivolumab)

Snippet

Sponsor: Centre Hospitalier Universitaire de Besancon | Conditions: Advanced Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED